AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

A novel EGFR-tyrosine kinase inhibitor (TKI), osimertinib, has marked efficacy in patients with EGFR-mutated lung cancer. However, some patients show intrinsic resistance and an insufficient response to osimertinib. This study showed that osimertinib stimulated AXL by inhibiting a negative feedback...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H. Araujo, Mariana Boroni, Akihiro Yoshimura, Shinsuke Shiotsu, Isao Matsumoto, Satoshi Watanabe, Toshiaki Kikuchi, Satoru Miura, Hiroshi Tanaka, Takeshi Kitazaki, Hiroyuki Yamaguchi, Hiroshi Mukae, Junji Uchino, Hisanori Uehara, Koichi Takayama, Seiji Yano
Materialtyp: Artigo
Språk:engelska
Publicerad: 2019
Länkar:https://doi.org/10.1038/s41467-018-08074-0
https://www.nature.com/articles/s41467-018-08074-0.pdf
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Internet

https://doi.org/10.1038/s41467-018-08074-0
https://www.nature.com/articles/s41467-018-08074-0.pdf

Liknande verk